ArticleCancer immunology, immunotherapy : CII2021

Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8

Rosmely Hernandez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.